Complex of tris(2-hydroxyethyl)amine with zinc bis[(2-methylphenoxy)acetate] as an aortic cholesterol esterase inhibitor in the experiment

The intramuscular administration of the complex of tris(2-hydroxyethyl)amine with zinc bis[(2-methylphenoxy)acetate] (Zitrimin), as an aqueous solution in a dose of 10 mg (kg of animal weight)(-1) for 2 months decreases activity of lysosomal lipolytic hydrolase (EC 3.1.1), cholesterol esterase (EC 3.1.1.13). Hence, the previously unknown feature of Zitrimin, that is, the ability to inhibit cholesterol esterase, attests to both structural and functional disorders of subcellular structures during development of atherosclerosis. The agents active towards such reactions can be useful in this case. Owing to the new properties, Zitrimin can be used to increase the vascular system stability to cholesterol during the atherosclerotic process. This expands the scope of applicability of this compound and gives prospects for development of new Zitrimin-based drugs for preventing the atherosclerotic vascular changes.

Automated summary

The study shows that Zitrimin can inhibit the activity of cholesterol esterase, helping to address subcellular structural issues during the development of atherosclerosis and providing prospects for the development of new drugs.